ezetimibe
A lipid-lowering drug that reduces cholesterol absorption, without the diabetes risk of statins.
As defined in 328 - Health Longevity
Other definitions
A drug that lowers LDL cholesterol by blocking cholesterol reabsorption in the gut, causing the liver to upregulate LDL receptors; less potent than statins but avoids synthesis inhibition
Peter Attia Dives Deep on STATINS (side effects & the best alternatives)
Where it comes up · 5
- Peter Attia Dives Deep on STATINS (side effects & the best alternatives)3 claims
- The longevity treatment no one’s talking about: Peter Attia, M.D. | mbg Podcast3 claims
- 328 - Health Longevity2 claims
- I Tried Statins — Here’s What Happened | Dr Nick Norwitz MD PhD2 claims
- Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]1 claim
Most important claims · 10 of 11Search all claims for “ezetimibe” →
- Ezetimibe is most effective in patients with defective ATP-binding cassette cholesterol transporters in the gut, which can be identified by measuring phytosterol levels; elevated phytosterol (particularly cytostanol and campesterol above normal) indicates impaired excretion and preserved absorption of plant sterols.Peter Attia Dives Deep on STATINS (side effects & the best alternatives)
- Statins (but not PCSK9 inhibitors, ezetimibe, or bempedoic acid) carry a small but real increased risk of type 2 diabetes, and a larger number of people become somewhat more glucose intolerant on statins—detectable via continuous glucose monitor but obscured on hemoglobin A1c—so patients showing a 5-10 point CGM change may be switched off statins despite tolerating them.328 - Health Longevity
- Ezetimibe reduces cholesterol absorption in the intestines by blocking the Niemann-Pick C1-like-1 protein (NPC1L1), a key transporter on intestinal cell surfaces, which prevents dietary and biliary cholesterol reabsorption and triggers compensatory LDL receptor upregulation on the liver.I Tried Statins — Here’s What Happened | Dr Nick Norwitz MD PhD
- PCSK9 inhibitors, ezetimibe, and bempedoic acid are the three main non-statin lipid-lowering drugs: PCSK9 inhibitors reduce LDL particle clearance; ezetimibe blocks cholesterol reabsorption in the gut via the liver; and bempedoic acid is a liver-specific cholesterol synthesis inhibitor (unlike statins which act globally), with typical out-of-pocket costs of ~$500/month for PCSK9 inhibitors and bempedoic acid.The longevity treatment no one’s talking about: Peter Attia, M.D. | mbg Podcast
- Because modern drugs (statins, PCSK9 inhibitors, ezetimibe, and coming CETP inhibitors) can eradicate apoB/LDL with essentially no side effects, diet should be used to fix metabolic problems while residual lipid problems should be addressed pharmacologically rather than through diet.328 - Health Longevity
- Lipid-lowering pharmacotherapy history: cholesterol-heart disease link identified ~1960, early treatments failed, statins introduced 1980s (~40 years ago) with benefit but high side effects, limiting prophylactic use; modern era (since ~2015) has seen development of PCSK9 inhibitors, ezetimibe, and bempedoic acid with minimal side effects.The longevity treatment no one’s talking about: Peter Attia, M.D. | mbg Podcast
- There is no justification for taking unnecessary risks with statins in high-risk individuals (those with APOE4 or family history of neurodegeneration) when alternative lipid-lowering drugs (PCSK9 inhibitors, ezetimibe, bempedoic acid) are available that do not affect brain cholesterol synthesis.Peter Attia Dives Deep on STATINS (side effects & the best alternatives)
- Reitano's cholesterol at age 30 was 230 with LDL of 130 to 140 and ApoB above 100, despite diet and exercise; stacking a statin, ezetimibe, Repatha, and a GLP-1 reduced LDL to about 10 and ApoB to below detection, with each drug dosed and tested independently.Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]
- Ezetimibe is more gut-specific than statins and is less likely to harm mitochondria based on its physiological mechanisms, since it targets intestinal cholesterol absorption rather than systemic metabolic pathways.I Tried Statins — Here’s What Happened | Dr Nick Norwitz MD PhD
- If cost were not a constraint, the speaker would likely prescribe PCSK9 inhibitors, ezetimibe, and bempedoic acid in combination or preference to statins, and expects this to become standard eventually once prices declinePeter Attia Dives Deep on STATINS (side effects & the best alternatives)